611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line

AzCH Nurse Assist Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...

Medical Disorders
Basic InformationLookupsLatest News
Health Tip: Understanding Muscle SpasmsBlack Patients May Not Gain Heart Benefit From Low-Dose AspirinIs Pot Use a Heart Risk After Surgery?E. Coli Outbreak Spurs Packaged Salad WarningHealth Tip: Should I Get a Cholesterol Test?Are Superbugs Making Themselves at Home in Your Makeup Bag?Sometimes, Aspirin May Be Enough to Ease MigrainesDangers of 'Superbug' Germs Greater Than BelievedAdditives to E-Cigarettes May Be Upping Health DangersMany Kids Traveling Overseas Aren't Vaccinated Against MeaslesVirtual Doc Visits Suffice for Many With Neurological DisordersBPA Levels in Humans Are Underestimated: StudyCleaner Air Quickly Brings Big Health Benefits, Study FindsAll 50 States Now Reporting Cases of Severe Vaping-Linked Lung Injury3 Drugs for Severe Epileptic Seizures Are Equally Effective: StudyStudy Casts Doubt on Use of Common Heart Failure Drugs'Mobile Stroke Units' Help Rush Treatment to PatientsDistracted by Their Smartphones, Pedestrians Are Landing in the ERVaping May Have Triggered Lung Illness Typically Only Seen in MetalworkersMore Than 100 E. Coli Illnesses Now Linked to Romaine LettuceLow-Dose Aspirin Might Cut Cancer Risk, Especially for Overweight PeopleEspecially in the Young, Cholesterol Is No Friend to the HeartAre E-Scooters a Quick Ticket to the ER?Uncontrolled Asthma a Danger to Pregnant Women, BabiesHealth Tip: Common Causes of Knee PainSome Cities' Smog Can Ruin Your VacationParkinson's Treatment Has Unexpected Side EffectHeart Attack at 44 Helped Her Realize Diabetes' DangersCleaner Teeth, Healthier Heart?Obesity Might Weaken Some Drugs' Effectiveness Against AFibHow to Prevent Holiday HeadachesAir Pollution May Up Glaucoma RiskHealth Tip: Causes of Stomach UlcersHealth Tip: Treating ShinglesLeg Pain Could Spell Peripheral Artery Disease for SomeEven in Small Doses, Air Pollution Harms Older AmericansDon't Let Allergies Spoil Your HolidaysGot Chronic Heartburn? Easy Does It During the Thanksgiving FeastAHA News: Flu Prevention Strategies Beyond Getting a Shot and Washing Your HandsUltrasound Treatment Might Ease Parkinson's TremorsPopular Heartburn Drugs May Up Odds of Stomach BugGunshot Wounds Have Long-Term Health Consequences: StudyU.S. Poison Centers Field More Calls About Psychoactive Substances: StudyMore E. coli Illnesses Linked to Tainted Romaine LettuceFDA Approves First System to Insert Ear Tubes Under Local AnesthesiaFDA Approves Oxbryta for Treatment of Sickle Cell DiseaseWhere 'Superbugs' Lurk in Your Home - and How to Stop ThemPlay It Safe With Holiday FoodsCaffeine, Cough Medicines: What's in the Average Blood TransfusionVitamin E Compound Likely Culprit Behind Vaping Lung Illnesses, Study Finds
Questions and AnswersLinksBook Reviews
Related Topics

Men's Health
Women's Health

Drug Duo May Be an Advance Against a Common Leukemia

HealthDay News
by -- Robert Preidt
Updated: Jul 31st 2019

new article illustration

WEDNESDAY, July 31, 2019 (HealthDay News) -- A two-drug combo helps patients with a common form of leukemia survive longer than the current standard of care, a new clinical trial finds.

The phase 3 trial of more than 500 U.S. patients with chronic lymphocytic leukemia (CLL) found that a combination of rituximab and ibrutinib extended patient survival.

Specifically, 89.4% of the patients who received the experimental drug combination did not have any progression of their leukemia about three years after treatment, compared with 72.9% of those who received the traditional chemotherapy combination.

As to overall survival, regardless of whether the disease had progressed or not, the trial found that three years after treatment, 98.8% of patients who received the two-drug combination were alive, compared with 91.5% of those who received the traditional treatment.

The research was led by Dr. Tait Shanafelt, professor of medicine at Stanford University, and will be published Aug. 1 in the New England Journal of Medicine. The study received funding from Pharmacyclics LLC, which makes ibrutinib.

Shanafelt and his team believe the results could change how most people with CLL are treated.

"These results will fully usher the treatment of chronic lymphocytic leukemia into a new era," Shanafelt said in a Stanford news release.

"We've found that this combination of targeted treatments is both more effective and less toxic than the previous standard of care for these patients," he added. "It seems likely that, in the future, most patients will be able to forgo chemotherapy altogether."

Patient Dan Rosenbaum, 57, was one of the participants randomly assigned to receive the dual drug treatment. In the news release, he said he felt an easing of symptoms very soon after the therapy began.

"I hadn't realized how fatigued I had become," Rosenbaum said. "I could barely play a single set of tennis, and I would be wiped out for days afterward. My lymph nodes were so swollen it was impossible to button the top button of my shirt collar. But within the first week of starting treatment, I noticed I had a little more spring in my step. After 10 days, there was a marked improvement in the size of my lymph glands. And after six weeks, my tumors were no longer detectable by physical exam."

The current standard treatment for CLL patients is an intravenous combination of three drugs -- fludarabine, cyclophosphamide and rituximab (FCR). Fludarabine and cyclophosphamide kill both healthy and cancerous cells by interfering with DNA replication, while rituximab targets immune system B cells that "run amok" in CLL, according to the researchers.

However, fludarabine and cyclophosphamide can cause significant side effects such as severe blood complications and life-threatening infections, the researchers said.

The new drug combination pairs rituximab with ibrutinib, which also specifically targets B cells.

"This is one of those situations we don't often have in oncology," Shanafelt explained. "The new treatment is both more effective and better tolerated. This represents a paradigm shift in how these patients should be treated. We can now relegate [traditional] chemotherapy to a fallback plan rather than a first-line course of action."

One expert in CLL care agreed that the findings might mark an advance.

"The major strength of this study is that it is a prospectively randomized comparison with the 'chemo-immunotherapy' combination FCR, in a large sample size," said Dr. Kanti Rai. He's a hematologist with the CLL Research and Treatment Program at Northwell Health Cancer Institute in New Hyde Park, N.Y.

The new study finds that the two-drug combo is now "superior" to the three-drug approach, Rai said. However, FCR might still work best in a subgroup of CLL patients whose cancer has certain genetic characteristics, he added.

More information

The American Cancer Society has more on CLL.